ダウンロード数: 225
このアイテムのファイル:
ファイル | 記述 | サイズ | フォーマット | |
---|---|---|---|---|
35_1451.pdf | 869.77 kB | Adobe PDF | 見る/開く |
タイトル: | 進行腎細胞癌に対するヒトリンパ芽球由来インターフェロン(HLBI)単独療法と抗癌剤との併用療法の比較 |
その他のタイトル: | Comparative clinical study of single and combination therapy of human lymphoblastoid interferon (HLBI) with 5-FU in the treatment of advanced renal cell carcinoma |
著者: | 浅川, 正純 前川, たかし 梅田, 優 坂本, 亘 千住, 将明 井関, 達男 仲谷, 達也 田中, 寛 堀井, 明範 山本, 啓介 川村, 正喜 森川, 洋二 山口, 哲男 柏原, 昇 川喜多, 順二 西島, 高明 松村, 俊宏 大山, 武司 西尾, 正一 早原, 信行 辻田, 正昭 和田, 誠次 安本, 亮二 岸本, 武利 前川, 正信 |
著者名の別形: | Asakawa, Masazumi Maekawa, Takashi Umeda, Masaru Sakamoto, Wataru Senju, Masaaki Iseki, Tatsuo Nakatani, Tatsuya Tanaka, Hiroshi Horii, Akinori Yamamoto, Keisuke Kawamura, Masaki Morikawa, Yoji Yamaguchi, Tetsuo Kashihara, Noboru Kawakita, Junji Nishijima, Takaaki Matsumura, Toshihiro Ohyama, Takeshi Nishio, Soichi Hayahara, Nobuyuki Tsujita, Masaaki Wada, Seiji Yasumoto, Ryoji Kishimoto, Taketoshi Maekawa, Masanobu |
キーワード: | Administration, Oral Aged Carcinoma, Renal Cell/drug therapy Drug Therapy, Combination Female Fluorouracil/administration & dosage/therapeutic use Humans Injections, Intramuscular Interferon Type I/administration & dosage/therapeutic use Kidney Neoplasms/drug therapy Male Middle Aged |
発行日: | Aug-1989 |
出版者: | 泌尿器科紀要刊行会 |
誌名: | 泌尿器科紀要 |
巻: | 35 |
号: | 8 |
開始ページ: | 1451 |
終了ページ: | 1455 |
抄録: | 進行腎細胞癌24症例に対して, HLBI単独療法と5-FU系抗癌剤との併用療法について比較検討した結果, 単独療法群11例中PR 3例で奏効率27.3%, 併用療法群13例中PRは1例で奏効率は7.7%であった.副作用は発熱が全例にみられたほか, GOT, GPT, LDH値の軽度上昇が4例に, 白血球数減少が2例にみられたが, いずれも可逆性で, HLBIの継続投与は可能であった A clinical trial using human lymphoblastoid interferon (HLBI) was done on patients with advanced renal cell carcinoma to compare the efficacy of monotherapy with that of combined administration with a 5-fluorouracil (FU) agent. A total of 24 patients with definitely diagnosed advanced renal cell carcinoma were enrolled in either of the HLBI treatments. Principally, the daily intramuscular injection of 3 million units of HLBI was done for 4 consecutive days and thereafter followed by twice of weekly injections. The combined agent used in the present study was 300 or 600 mg of 5-fluorouracil agent given orally. The efficacy of HLBI was evaluated according to direct assessment standard of chemotherapy to a solid tumor expelled by the committee of Japanese health and welfare ministry. Of 11 patients who received monotherapy, 3 had a partial response rate of 27.3 percent. While only one of 13 patients having received combined HLBI administration with oral 5-FU tablets showed a partial response with a response rate of 7.7 percent. A total of 4 patients partially responded to either HLBI treatment with a subsequent response of 16.7 percent. Partial response implied reduction of lung metastatic foci in 3 patients and primary lesion in one patient. There was observed untoward fever-up in all patients with HLBI injections which was relieved with acquired tachyphylaxis owing to repeated injections. Otherwise minimal adverse effects were temporary elevation of liver transaminase in 4 and leucopenia in 2 patients during the HLBI treatment both of which eventually returned to the normal level without discontinuation of HLBI therapy.(ABSTRACT TRUNCATED AT 250 WORDS) |
URI: | http://hdl.handle.net/2433/116619 |
PubMed ID: | 2816609 |
出現コレクション: | Vol.35 No.8 |
このリポジトリに保管されているアイテムはすべて著作権により保護されています。